PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Efinopegdutide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Efinopegdutide is a GLP-1 and glucagon receptor co-agonist given by subcutaneous injection once a week. · pmid:37355043

In a 24-week phase IIa study in non-alcoholic fatty liver disease, liver fat fell by 72.7% from baseline with efinopegdutide against 42.3% with semaglutide, with more gastrointestinal adverse events on efinopegdutide. · pmid:37355043

Identity

No public registry record is shown for this page: PubChem gave no record that proves it is this substance.

Where the evidence actually sits

Emerging100%

Proportion of the 1 claim about Efinopegdutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. (2023) · emerging20232023

1 resolved citation, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Efinopegdutide yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. · pmid 37355043 · 2023
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

1 resolved citation, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.